Long-term suppression of hyperparathyroidism by phosphate binders in uremic children
- 1 January 1987
- journal article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 1 (2) , 145-149
- https://doi.org/10.1007/bf00849285
Abstract
Forty-five children with stable chronic renal failure, not on dialysis, were treated conservatively with a regimen of mild dietary phosphate restriction and high-dose phosphate binders for up to 5 years. Both aluminum hydroxide and calcium carbonate were used initially, but almost all patients were taking calcium carbonate towards the end of the period. Serum immunoreactive parathyroid hormone concentrations were significantly decreased and were within the normal range after 1 year and remained normal during treatment. There was no significant change in renal function over the same treatment period. We conclude that calcium carbonate should be used as the phosphate binder of choice in the long-term suppression of hyperphosphatemia and hyperparathyroidism in uremic children.Keywords
This publication has 22 references indexed in Scilit:
- Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide.BMJ, 1985
- Aluminum loading in children with chronic renal failureKidney International, 1984
- Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.Journal of Clinical Investigation, 1984
- Aluminum Intoxication from Aluminum-Containing Phosphate Binders in Children with Azotemia Not Undergoing DialysisNew England Journal of Medicine, 1984
- Effect of aluminium hydroxide on serum ionised calcium, immunoreactive parathyroid hormone, and aluminium in chronic renal failure.BMJ, 1982
- Reversal of hyperparathyroidism in response to dietary phosphorus restriction in the uremic dogKidney International, 1979
- DETERIORATION OF RENAL FUNCTION DURING TREATMENT OF CHRONIC RENAL FAILURE WITH 1,25- DIHYDROXYCHOLECALCIFEROLThe Lancet, 1978
- CONTROLLED TRIAL OF 1α-HYDROXYCHOLECALCIFEROL IN CHRONIC RENAL FAILUREThe Lancet, 1976
- On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using “proportional reduction” of dietary phosphorus intakeKidney International, 1972
- On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dogJournal of Clinical Investigation, 1971